# TK216 in Patients With Relapsed or Refractory Ewing Sarcoma

> **NCT02657005** · PHASE1,PHASE2 · TERMINATED · sponsor: **Oncternal Therapeutics, Inc** · enrollment: 85 (actual)

## Conditions studied

- Sarcoma, Ewing

## Interventions

- **DRUG:** TK216

## Key facts

- **NCT ID:** NCT02657005
- **Lead sponsor:** Oncternal Therapeutics, Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2016-08
- **Primary completion:** 2022-05
- **Final completion:** 2022-06
- **Target enrollment:** 85 (ACTUAL)
- **Why stopped:** Sponsor Decision
- **Last updated:** 2025-02-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02657005

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02657005, "TK216 in Patients With Relapsed or Refractory Ewing Sarcoma". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT02657005. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*